Japan's MHLW names Tomonori Nakayama to key reimbursement post

Japan PM Abe
Japan

Japan's Ministry of Health, Labor and Welfare (MHLW) announced a series of in-house moves that include naming Tomonori Nakayama as pharmaceutical management director at the Health Insurance Bureau's Medical Economics Division, a key post that advises on price reforms.

The bureau advises Japan's Central Social Insurance Medical Council known as Chuikyo. Nakayama was previously director of the Office of Review Management at the Pharmaceuticals and Medical Devices Agency (PMDA).

The reimbursement agency has been a focal point for the government led by Prime Minister Shinzo Abe to curb growing drug costs with a focus on best-selling newer therapies and a push to use more generic medicines.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The previous holder of the post, Kiyohito Nakai, was seconded to the National Cancer Center.

In other moves, Health Minister Yasuhisa Shiozaki retained Vice Health Minister Kazuo Futagawa in the top civil service post as well as Kazuhiko Mori, the councilor in charge of pharmaceuticals at the minister’s Secretariat.

Starting this week, Shiozaki has separated the Pharmaceutical Safety and Environmental Health Bureau’s Evaluation and Licensing Division into separate units with responsibility for drug and medical device reviews respectively.

Yasuhiro Suzuki, director general for technology policy coordination, will assume the role of director general of the Health Insurance Bureau. The current bureau chief, Takeshi Karasawa, will move to the Cabinet Secretariat.

In other appointments, Daisaku Sato will move to the post of director of the Pharmaceutical Safety and Environmental Health Bureau’s Safety Division with responsibility for medical database MID-NET, from his role as head of the PMDA’s Office of Cellular and Tissue-based Products.

Shiozaki also appointed Atsushi Ichinose as chief of the Blood and Blood Products Division of the Pharmaceutical Safety and Environmental Health Bureau, while Keiko Morimitsu was named to helm the Health Policy Bureau’s Research and Development Division, with a bill on clinical research rules now before parliament as part of her remit.

- here's the MHLW website

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.